Novocure Limited (NVCR)

$19.02

+0.37

(+1.98%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $17.85
    $19.10
    $19.02
    downward going graph

    6.15%

    Downside

    Day's Volatility :6.52%

    Upside

    0.39%

    downward going graph
  • $10.87
    $41.51
    $19.02
    downward going graph

    42.85%

    Downside

    52 Weeks Volatility :73.81%

    Upside

    54.18%

    downward going graph

Returns

PeriodNovocure LimitedSector (Health Care)Index (Russel 2000)
3 Months
47.61%
6.5%
0.0%
6 Months
31.25%
7.1%
0.0%
1 Year
-53.77%
9.8%
0.0%
3 Years
-89.86%
14.2%
-20.2%

Highlights

Market Capitalization
2.0B
Book Value
$3.34
Earnings Per Share (EPS)
-1.81
PEG Ratio
-0.47
Wall Street Target Price
28.33
Profit Margin
-36.67%
Operating Margin TTM
-28.51%
Return On Assets TTM
-11.18%
Return On Equity TTM
-48.7%
Revenue TTM
525.7M
Revenue Per Share TTM
4.92
Quarterly Revenue Growth YOY
13.4%
Gross Profit TTM
423.6M
EBITDA
-195.6M
Diluted Eps TTM
-1.81
Quarterly Earnings Growth YOY
-0.06
EPS Estimate Current Year
-1.62
EPS Estimate Next Year
-1.72
EPS Estimate Current Quarter
-0.42
EPS Estimate Next Quarter
-0.44

Analyst Recommendation

Buy
    61%Buy
    38%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Novocure Limited(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
5
5
5
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 48.95%

Current $19.02
Target $28.33

Company Financials

FY18Y/Y Change
Revenue
248.1M
↑ 40.13%
Net Income
-63.6M
↑ 3.08%
Net Profit Margin
-25.62%
↑ 9.21%
FY19Y/Y Change
Revenue
351.3M
↑ 41.62%
Net Income
-7.2M
↓ 88.62%
Net Profit Margin
-2.06%
↑ 23.56%
FY20Y/Y Change
Revenue
494.4M
↑ 40.72%
Net Income
19.8M
↓ 373.97%
Net Profit Margin
4.01%
↑ 6.07%
FY21Y/Y Change
Revenue
535.0M
↑ 8.23%
Net Income
-58.4M
↓ 394.58%
Net Profit Margin
-10.91%
↓ 14.92%
FY22Y/Y Change
Revenue
537.8M
↑ 0.53%
Net Income
-92.5M
↑ 58.58%
Net Profit Margin
-17.2%
↓ 6.29%
FY23Y/Y Change
Revenue
509.3M
↓ 5.3%
Net Income
-207.0M
↑ 123.75%
Net Profit Margin
-40.65%
↓ 23.45%
Q4 FY22Q/Q Change
Revenue
128.4M
↓ 1.96%
Net Income
-37.3M
↑ 40.36%
Net Profit Margin
-29.05%
↓ 8.76%
Q1 FY23Q/Q Change
Revenue
122.2M
↓ 4.86%
Net Income
-53.1M
↑ 42.24%
Net Profit Margin
-43.43%
↓ 14.38%
Q2 FY23Q/Q Change
Revenue
126.1M
↑ 3.17%
Net Income
-57.4M
↑ 8.21%
Net Profit Margin
-45.55%
↓ 2.12%
Q3 FY23Q/Q Change
Revenue
127.3M
↑ 1.01%
Net Income
-49.5M
↓ 13.82%
Net Profit Margin
-38.87%
↑ 6.68%
Q4 FY23Q/Q Change
Revenue
133.8M
↑ 5.08%
Net Income
-47.1M
↓ 4.86%
Net Profit Margin
-35.19%
↑ 3.68%
Q1 FY24Q/Q Change
Revenue
138.5M
↑ 3.53%
Net Income
-38.8M
↓ 17.67%
Net Profit Margin
-27.98%
↑ 7.21%
FY18Y/Y Change
Total Assets
339.8M
↑ 28.08%
Total Liabilities
227.5M
↑ 49.96%
FY19Y/Y Change
Total Assets
479.4M
↑ 41.1%
Total Liabilities
261.7M
↑ 15.0%
FY20Y/Y Change
Total Assets
1.1B
↑ 119.42%
Total Liabilities
575.5M
↑ 119.93%
FY21Y/Y Change
Total Assets
1.1B
↑ 8.32%
Total Liabilities
729.0M
↑ 26.68%
FY22Y/Y Change
Total Assets
1.2B
↑ 4.58%
Total Liabilities
750.5M
↑ 2.95%
FY23Y/Y Change
Total Assets
1.1B
↓ 3.82%
Total Liabilities
783.6M
↑ 4.42%
Q4 FY22Q/Q Change
Total Assets
1.2B
↑ 1.48%
Total Liabilities
750.5M
↑ 2.97%
Q1 FY23Q/Q Change
Total Assets
1.2B
↓ 1.45%
Total Liabilities
742.2M
↓ 1.1%
Q2 FY23Q/Q Change
Total Assets
1.2B
↓ 1.3%
Total Liabilities
743.3M
↑ 0.15%
Q3 FY23Q/Q Change
Total Assets
1.1B
↓ 1.09%
Total Liabilities
752.6M
↑ 1.25%
Q4 FY23Q/Q Change
Total Assets
1.1B
↓ 0.02%
Total Liabilities
783.6M
↑ 4.12%
Q1 FY24Q/Q Change
Total Assets
1.1B
↓ 2.16%
Total Liabilities
762.1M
↓ 2.75%
FY18Y/Y Change
Operating Cash Flow
-1.9M
↓ 94.37%
Investing Cash Flow
-5.5M
↓ 163.66%
Financing Cash Flow
69.4M
↑ 1242.28%
FY19Y/Y Change
Operating Cash Flow
26.6M
↓ 1527.35%
Investing Cash Flow
-51.7M
↑ 840.6%
Financing Cash Flow
61.7M
↓ 11.08%
FY20Y/Y Change
Operating Cash Flow
99.1M
↑ 272.46%
Investing Cash Flow
-472.8M
↑ 815.18%
Financing Cash Flow
440.2M
↑ 613.69%
FY21Y/Y Change
Operating Cash Flow
82.8M
↓ 16.53%
Investing Cash Flow
-144.8M
↓ 69.37%
Financing Cash Flow
25.7M
↓ 94.16%
FY22Y/Y Change
Operating Cash Flow
30.8M
↓ 62.8%
Investing Cash Flow
-140.0M
↓ 3.37%
Financing Cash Flow
15.5M
↓ 39.73%
Q4 FY22Q/Q Change
Operating Cash Flow
-3.7M
↓ 116.53%
Investing Cash Flow
-128.1M
↓ 14.77%
Financing Cash Flow
3.4M
↓ 18.89%
Q1 FY23Q/Q Change
Operating Cash Flow
-16.7M
↑ 351.23%
Investing Cash Flow
82.3M
↓ 164.26%
Financing Cash Flow
5.2M
↑ 52.61%
Q2 FY23Q/Q Change
Operating Cash Flow
-22.7M
↑ 35.93%
Investing Cash Flow
-13.9M
↓ 116.89%
Financing Cash Flow
7.5M
↑ 44.16%
Q3 FY23Q/Q Change
Operating Cash Flow
-19.3M
↓ 15.05%
Investing Cash Flow
17.3M
↓ 224.19%
Financing Cash Flow
1.2M
↓ 84.39%

Technicals Summary

Sell

Neutral

Buy

Novocure Limited is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Novocure Limited
Novocure Limited
2.7%
31.25%
-53.77%
-89.86%
-76.37%
Stryker Corporation
Stryker Corporation
-3.84%
5.16%
12.86%
24.25%
52.69%
Boston Scientific Corp.
Boston Scientific Corp.
-3.68%
21.48%
41.72%
68.89%
76.47%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-34.8%
-18.49%
-34.85%
-45.17%
-15.86%
Abbott Laboratories
Abbott Laboratories
1.03%
-5.4%
-7.12%
-11.35%
20.75%
Medtronic Plc
Medtronic Plc
-1.99%
-9.34%
-13.21%
-38.74%
-23.49%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Novocure Limited
Novocure Limited
NA
NA
-0.47
-1.62
-0.49
-0.11
NA
3.34
Stryker Corporation
Stryker Corporation
38.91
38.91
2.92
11.95
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
63.22
63.22
1.8
2.37
0.09
0.05
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
36.4
36.4
5.19
2.76
0.22
0.12
NA
12.35
Abbott Laboratories
Abbott Laboratories
33.84
33.84
5.99
4.66
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
28.97
28.97
1.52
5.2
0.07
0.04
0.04
38.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Novocure Limited
Novocure Limited
Buy
$2.0B
-76.37%
NA
-36.67%
Stryker Corporation
Stryker Corporation
Buy
$129.7B
52.69%
38.91
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$114.3B
76.47%
63.22
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$52.4B
-15.86%
36.4
23.74%
Abbott Laboratories
Abbott Laboratories
Buy
$186.6B
20.75%
33.84
13.65%
Medtronic Plc
Medtronic Plc
Buy
$102.5B
-23.49%
28.97
11.36%

Insights on Novocure Limited

  • Increasing Revenue

    Revenue is up for the last 5 quarters, 122.18M → 138.50M (in $), with an average increase of 3.1% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 4 quarters, -57.41M → -38.76M (in $), with an average increase of 14.2% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 41.7% return, outperforming this stock by 95.5%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 68.9% return, outperforming this stock by 158.8%

Institutional Holdings

  • FMR Inc

    14.93%

  • Vanguard Group Inc

    9.32%

  • BlackRock Inc

    8.44%

  • Capital Research & Mgmt Co - Division 3

    8.24%

  • State Street Corporation

    3.13%

  • T. Rowe Price Associates, Inc.

    2.21%

Corporate Announcements

  • Novocure Limited Earnings

    Novocure Limited’s price-to-earnings ratio stands at None

    Read More

Company Information

we are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia.

Organization
Novocure Limited
Employees
1453
CEO
Mr. William F. Doyle
Industry
Health Technology

Discover More

FAQs